NCT01720316View on ClinicalTrials.gov

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 10, 2012

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Schizo-affective DisorderBipolar Disorder
Interventions
DRUG

Glycine

Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine

DRUG

placebo

Trial Locations (1)

02478

McLean Hospital, Belmont

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Mclean Hospital

OTHER

NCT01720316 - Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders | Biotech Hunter | Biotech Hunter